{"id":"W2973731620","doi":"10.1136/ijgc-2019-igcs.1","title":"1 MILO/ENGOT-OV11: Phase-3 study of binimetinib versus physician’s choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum","year":2019,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; KRAS; Selumetinib; MEK inhibitor; Chemotherapy; Clinical endpoint; Internal medicine; Serous carcinoma; Progression-free survival; Ovarian cancer; Oncology; Gastroenterology; Serous fluid; Surgery; Randomized controlled trial; Cancer; MAPK/ERK pathway; Kinase; Colorectal cancer; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009805938,0.001060425,0.001366658,0.0003760328,0.0003996624,0.00120105,0.0007621337,0.001207625,0.009963987],"category_scores_gemma":[0.0009288865,0.0004503819,0.00133813,0.0003537457,0.0006047552,0.0008436177,0.0002981102,0.003523817,0.00130776],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00109399,"about_ca_system_score_gemma":0.0009707147,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001706356,"about_ca_topic_score_gemma":0.01178564,"domain_scores_codex":[0.9997739,0.00009249499,0.000009693684,0.00004548464,0.00002291891,0.00005558357],"domain_scores_gemma":[0.99967,0.0000628664,0.00006223724,0.0000188111,0.0000195405,0.0001665266],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6951001,0.02268988,0.007253238,0.002992092,0.003306473,0.0002349464,0.0003039267,0.003990865,0.01964135,0.001237343,0.0381032,0.2051466],"study_design_scores_gemma":[0.7485831,0.2020825,0.01736834,0.0003090585,0.001913566,0.0004341766,0.0001485711,0.002785335,0.003252566,0.0008839162,0.02215091,0.00008791422],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9474858,0.01697169,0.001171272,0.00539964,0.001125543,0.002856664,0.01092453,0.0003141305,0.01375079],"genre_scores_gemma":[0.9592213,0.00760134,0.002777983,0.004289542,0.0003093373,0.001759659,0.009653863,0.0001031405,0.01428386],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009963987,"threshold_uncertainty_score":0.03333288,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05509890882951412,"score_gpt":0.3621649320535733,"score_spread":0.3070660232240592,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}